Brustzentrum Rhein-Ruhr Servicegesellschaft mbH

At Brustzentrum Rhein-Ruhr Servicegesellschaft mbH, much of the clinical trial activity focuses on neoplasms, especially breast cancer and HER2-positive disease. The studies are designed to test new treatment options, compare them with current standards, and improve outcomes for people with early, locally advanced, or metastatic breast cancer.

• High-risk HER2-positive early breast cancer and residual disease after surgery
• HER2-positive unresectable locally recurrent or metastatic breast cancer
• HER2-negative and hormone receptor-positive breast cancer across early and advanced stages
• Triple-negative breast cancer, including locally advanced and metastatic forms

Research here often evaluates whether newer targeted therapies and antibody-based treatments can improve survival, reduce recurrence, or increase the chance of a complete response compared with established care.

This site also has a strong focus on hormonal diseases, particularly breast cancers driven by estrogen receptor and hormone receptor signaling. These trials aim to refine endocrine-based treatment, delay progression, and identify better options for people whose disease has returned or spread after prior hormone therapy.

• HR+/HER2-negative advanced breast cancer
• ER-positive, HER2-negative early breast cancer with higher risk of recurrence
• ESR1-mutated advanced breast cancer after endocrine therapy and CDK4/6 inhibitor treatment
• Endocrine-responsive early breast cancer and adjuvant treatment strategies

Several studies explore whether combining endocrine therapy with new targeted medicines can improve disease control, extend progression-free survival, and support more personalized treatment choices.

Another major area of research at this hospital/clinic is treatment for early breast cancer, especially cases with a higher risk of recurrence. The trials are focused on improving adjuvant and neoadjuvant care, with the goal of reducing the chance that cancer returns after initial treatment.

• Node-positive, HER2-negative early breast cancer
• HER2-positive early breast cancer with high-risk features
• Triple-negative early breast cancer with residual invasive disease
• Intermediate- to high-risk early breast cancer requiring tailored therapy

These studies are evaluating whether newer medicines and personalized treatment approaches can improve invasive disease-free survival and pathological response while keeping treatment effective and more precisely matched to risk.

Beyond cancer control, the trial portfolio includes supportive care research aimed at improving daily well-being for people receiving breast cancer treatment. One important topic is the management of moderate to severe vasomotor symptoms, which can affect quality of life during endocrine therapy.

• Vasomotor symptoms linked to adjuvant endocrine treatment
• Quality of life during long-term breast cancer therapy
• Symptom relief in women with hormone receptor-positive disease
• Supportive treatment alongside active cancer therapy

These studies are intended to reduce treatment-related discomfort and help patients stay on effective cancer therapy with better tolerability and day-to-day functioning.

The research program at Brustzentrum Rhein-Ruhr also includes efforts to make breast cancer care more personalized. Some trials examine whether diagnostic tools and biomarker-guided strategies can better match treatment to the individual patient and improve the balance between benefit and burden.

• HER2DX-guided treatment selection in early breast cancer
• Biomarker-informed decisions in high-risk disease
• Immune-related and genetic features influencing treatment response
• Personalized approaches for both early-stage and advanced breast cancer

Overall, this research is aimed at improving diagnostic precision, identifying who is most likely to benefit from specific therapies, and supporting more individualized breast cancer care.